Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

574.35INR
10:44am IST
Change (% chg)

Rs3.50 (+0.61%)
Prev Close
Rs570.85
Open
Rs573.50
Day's High
Rs575.95
Day's Low
Rs570.20
Volume
233,752
Avg. Vol
1,582,629
52-wk High
Rs660.00
52-wk Low
Rs457.45

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.51
Market Cap(Mil.): Rs462,332.91
Shares Outstanding(Mil.): 804.27
Dividend: 2.00
Yield (%): 0.35

Financials

  CIPL.NS Industry Sector
P/E (TTM): 55.49 30.14 30.77
EPS (TTM): 10.36 -- --
ROI: 5.76 15.85 15.23
ROE: 6.92 16.96 16.56

MEDIA-India's Cipla in talks to sell animal health unit - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

28 Nov 2016

MEDIA-India's Cipla plans to get more aggressive in US, UK - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

17 Nov 2016

Cipla Q2 profit falls as Europe, emerging markets suffer

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.

09 Nov 2016

UPDATE 1-India's Cipla Q2 profit falls as Europe, emerging markets suffer

MUMBAI, Nov 9 Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.

09 Nov 2016

India's Cipla Q2 profit falls 35 pct

MUMBAI, Nov 9 Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates.

09 Nov 2016

BRIEF-Cipla Sept qtr consol profit falls

* Consensus forecast for Sept quarter consol net profit was 3.92 billion rupees

09 Nov 2016

BRIEF-Cipla gets EIR from USFDA for its Indore facility

* Cipla receives EIR from the US FDA for its Indore facility Source text: http://bit.ly/2e8Sy2g Further company coverage: (Bengaluru newsroom)

12 Oct 2016

MEDIA-India's Cipla to freeze increments of about 400 top managers - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

29 Sep 2016

Morning News Call - India, August 16

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08162016.pdf FACTORS TO WATCH 9:30 am: RBI Governor Raghuram Rajan and Deputy Governor S.S. Mundra at FICCI-IBA annual banking conference in Mumbai. 12:00 pm: Government to release July wholesale price inflation data in New Delhi. 4:30 pm: Banks Board Bureau Chairman Vinod Rai delivers a lecture at central vigilance commission event in New Delhi.

16 Aug 2016

Cipla first quarter profit lags estimates; names new CEO

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, reported a lower-than-expected quarterly profit as revenues in its home market were hit by government measures to cut drug prices.

12 Aug 2016

Earnings vs. Estimates